Over the last year, the focus shifted towards mucosal COVID vaccinations, which included nasal and "swish and swallow" oral vaccines. Now, researchers are developing a Covid-19 vaccine that people might drink rather than getting a shot via needle. According to a new report by CNET, the QYNDR vaccine has finished its phase 1 clinical trial and is awaiting further funds to carry out the more extensive, advanced experiments that could bring the vaccine to market.

According to Dr. Kyle Flanigan, founder of US Specialty Formulations, the manufacturer of QYNDR, the oral vaccine is much "kinder" because of its nicer approach towards the route of administration. The report noted that the outcome of the clinical trial from New Zealand was encouraging, which gives hope that the QYNDR vaccine is a viable option for defence against the slew of COVID-19 variations currently in circulation.

Dr. Flanigan explained that it is extremely difficult for any vaccination to endure passing through the digestive system. They added that the acids in the stomach break down the vaccine, making it ineffective; however, with this vaccine, they were able to figure out how to get a vaccine past the stomach and into the gut and have it be effective and induce the appropriate response. 

(Source: https://www.daijiworld.com/news/newsDisplay?newsID=1042757 )